Reporter Phages for Diagnosis of Drug-Resistant TB in HIV High-Burden Populations

报告噬菌体用于诊断 HIV 高负担人群中的耐药结核病

• 批准号: 8697724
• 负责人: WILLIAM Robert JACOBS
• 金额: $ 51.41万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-15 至 2015-03-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8697724
• 关键词: AIDS/HIV problem; Acid Fast Bacillae Staining Method; Acquired Immunodeficiency Syndrome; Address; Antibiotic Therapy; Antimycobacterial Agents; Bacillus (bacterium); Bacteriophages; Biological Assay; Biological Markers; Case Fatality Rates; Cells; Characteristics; Chronic; Clinic; Clinical; Collaborations; Communities; Complex; Diagnosis; Diagnostic; Diagnostics Research; Drug Resistant Tuberculosis; Drug resistance; Drug resistance in tuberculosis; Drug-sensitive; Epidemic; Extreme drug resistant tuberculosis; Fluorescence; Funding; Genes; HIV; Hospital Referrals; Human; Incidence; Infection; Institutes; Laboratories; Medicine; Metabolic; Minimum Inhibitory Concentration measurement; Molecular; Mycobacteriophages; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Newly Diagnosed; Patients; Pharmaceutical Preparations; Phenotype; Population; Predisposition; Prevalence; Prevention; Public Health; Recombinants; Regimen; Reporter; Research; Research Institute; Research Personnel; Resistance; Rifampicin resistance; Role; Sampling; Scientist; Sensitivity and Specificity; South Africa; Sputum; Survivors; Techniques; Testing; Treatment Failure; Treatment outcome; Tuberculosis; Visual; Work; chemotherapy; college; drug isolation; improved; in vivo; in vivo Model; innovation; killings; mycobacterial; novel; prevent; programs; promoter; research facility; resistant strain; transmission process; treatment duration; tuberculosis drugs; tuberculosis treatment

DESCRIPTION (provided by applicant): Nowhere has drug-resistant TB generated more alarm than in South Africa, where synergies between endemic TB and HIV have caused 'explosive' increases in TB incidence and case- fatality rates. The most resistant form of TB, extensively drug resistant tuberculosis (XDR-TB), is increasingly prevalent in South Africa. An important obstacle to improving survival for XDR-TB is the lack of a rapid, biomarker that serves to identify viable Mtb, allow drug susceptibility testing in clinical sputum samples and detect Mtb persisters. Utilizing three novel recombinant reporter mycobacteriophages, we have developed assays with superior test characteristics that will allow us to characterize complex drug resistance and mycobacterial persistence in vivo to improve treatment outcomes for drug-resistant TB/HIV patients. This proposal is a result of an ongoing funded collaboration between researchers at Albert Einstein College of Medicine, the KwaZulu-Natal Research Institute for Research in Tuberculosis and HIV/AIDS (K-RITH), and the Centre for AIDS Programme of Research in South Africa (CAPRISA). This is an innovative approach with the potential to make a substantial impact in our ability to rapidly diagnose drug-resistant tuberculosis thereby improving treatment outcomes, reducing transmission and preventing amplification of drug resistance on treatment.

描述（由申请人提供）：耐药结核病在南非引起的恐慌最为严重，当地结核病和艾滋病毒之间的协同作用导致结核病发病率和病死率“爆炸式”增加。耐药性最强的结核病——广泛耐药结核病 (XDR-TB) 在南非日益流行。提高广泛耐药结核病生存率的一个重要障碍是缺乏快速的生物标志物来识别活的结核分枝杆菌，允许在临床痰样本中进行药物敏感性测试并检测结核分枝杆菌 坚持者。利用三种新型重组报告分枝杆菌噬菌体，我们开发了具有卓越测试特性的检测方法，使我们能够表征复杂的耐药性和体内分枝杆菌的持久性，以改善耐药结核病/艾滋病毒患者的治疗结果。该提案是阿尔伯特·爱因斯坦医学院、夸祖鲁-纳塔尔省结核病和艾滋病毒/艾滋病研究所 (K-RITH) 以及南非艾滋病研究计划中心的研究人员持续资助合作的结果（卡普里萨）。这是一种创新方法，有可能对我们快速诊断耐药结核病的能力产生重大影响，从而改善治疗结果、减少传播并防止治疗中耐药性的放大。